BUSINESS
Zeria Obtains Exclusive Rights in Japan for Iron Deficiency Treatment Ferinject from Vifor Pharma of Switzerland
Zeria Pharmaceutical announced on August 19 that it has entered into an exclusive license agreement with Vifor Pharma of Switzerland (Zurich) to develop and commercialize the iron deficiency treatment Ferinject (ferric carboxymaltose) in Japan. The terms and conditions of the…
To read the full story
Related Article
- Zeria Files Iron Deficiency Med in Japan
April 2, 2018
BUSINESS
- Takeda Turns the Page to Kim’s “10-Year” Era, Betting on New Drugs and AI
June 26, 2026
- Sangamo Files Chapter 11, Astellas and Lilly Eye Key Assets
June 26, 2026
- Otsuka’s Centanafadine Meets PIII Goal in ADHD Patients with Anxiety
June 26, 2026
- Shionogi Welcomes Government Roadmap’s Focus on Infectious Diseases
June 26, 2026
- Sawai Cleared to Manufacture Nichi-Iko’s Lipitor Generic
June 26, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





